Overview

A Bioequivalence Study Between Telmione 80 mg and Micardis 80 mg in Healthy Adult Volunteers

Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
To compare the pharmacokinetics and safety after a single dose administration of Telmione® 80 mg and Micardis® 80 mg in healthy adult volunteers
Phase:
Phase 1
Details
Lead Sponsor:
HK inno.N Corporation
Treatments:
Telmisartan